Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1

Better treatments are needed for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of failing standard therapy. Avoiding apoptosis is a hallmark of cancer, and in DLBCL the redundantly functioning anti-apoptotic proteins BCL2 and MCL1 are frequently expressed. Here, we explore drugs t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Li, Lingxiao, Pongtornpipat, Praechompoo, Tiutan, Timothy, Kendrick, Samantha L., Park, Soyoung, Persky, Daniel O., Rimsza, Lisa M., Puvvada, Soham D., Schatz, Jonathan H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4526343/
https://ncbi.nlm.nih.gov/pubmed/25882699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.99
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados